Novavax (NVAX) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to -$202.4 million.
- Novavax's Income from Continuing Operations fell 6684.17% to -$202.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $341.7 million, marking a year-over-year increase of 21997.03%. This contributed to the annual value of -$187.5 million for FY2024, which is 6560.04% up from last year.
- Per Novavax's latest filing, its Income from Continuing Operations stood at -$202.4 million for Q3 2025, which was down 6684.17% from $106.5 million recorded in Q2 2025.
- Novavax's Income from Continuing Operations' 5-year high stood at $518.6 million during Q1 2025, with a 5-year trough of -$846.3 million in Q4 2021.
- Moreover, its 5-year median value for Income from Continuing Operations was -$168.6 million (2022), whereas its average is -$142.7 million.
- Its Income from Continuing Operations has fluctuated over the past 5 years, first plummeted by 191082.7% in 2021, then soared by 45150.53% in 2025.
- Over the past 5 years, Novavax's Income from Continuing Operations (Quarter) stood at -$846.3 million in 2021, then skyrocketed by 78.46% to -$182.2 million in 2022, then increased by 2.12% to -$178.4 million in 2023, then surged by 54.58% to -$81.0 million in 2024, then plummeted by 149.76% to -$202.4 million in 2025.
- Its Income from Continuing Operations stands at -$202.4 million for Q3 2025, versus $106.5 million for Q2 2025 and $518.6 million for Q1 2025.